Since UCH-L1 seems to be expressed mainly in metastatic carcinomas and not in primary carcinomas, small-molecule inhibitors specifically inhibiting C-terminal farnesylation of UCH-L1 (63) might reduce the proinvasive properties of exosomes from LMP1-positive cancer cells and therefore might represent promising candidates for antimetastasis drug development. Here, PDLIM7 is linked to carcinoma.